EUCTR2018-004261-14-NO进行中（未招募）1 期
MUscle Side-Effects of atorvastatin in coronary patients (MUSE) - MUscle Side-Effects of atorvastatin
Vestre Viken Trust0 个研究点目标入组 120 人开始时间: 2018年11月21日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •First or recurrent diagnosis (myocardial infarction) or treatments (PCI or CABG) for a CHD event 6-36 months prior to study start and prescribed atorvastatin.
- •Self-reported muscle complaints (i.e. pain, weakness, tenderness, stiffness or cramp to the body of any intensity) that they attribute to atorvastatin therapy at study inclusion
- •Self-reported muscle complaints that has led to atorvastatin discontinuation at study inclusion.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •First or recurrent diagnosis (myocardial infarction) or treatments (PCI or CABG) for a CHD event the past 12 months prior to study start in high risk patients (i.e. at least one of following comorbid conditions: systolic heart failure, >1 previous myocardial infarction, kidney failure, diabetes, and smokers)
- •First or recurrent diagnosis (myocardial infarction) or treatments (PCI or CABG) for a CHD event the past 6 months prior to study start in low risk patients without any of the co-morbid conditions mentioned above and in patients who are not taking a statin at all
- •Patients with residual stenosis on the major coronary arteries that were not revascularized at the time of the index event, patents with symptomatic peripheral artery disease and patients with familial hypercholesterolemia
- •Patient has any contraindications for atorvastatin listed in the Summary of Product Characteristics (i.e. known hypersensitivity to the ingredients, acute liver failure/ ALT > 3 times upper limit of the normal range in blood at study start, pregnancy and breastfeeding )
- •History of previous rhabdomyolysis, myopathy or liver failure due to statin treatment with CK > 10 times upper limit of the normal range or ALT > 3 times upper limit of the normal range.
- •Any condition (e.g. psychiatric illness, dementia) or situation, that in the investigator’s opinion could put the subject at significant risk, confound the study results, interfere significantly with the subject participation in the study, or rendering informed consent unfeasible
- •Short life expectancy due to other medical conditions
- •Not being able to understand Norwegian.
- •Women of childbearing potential defined as a premenopausal female capable of becoming pregnant.
- •Participation in another randomized clinical trial
研究者
相似试验
已完成
4 期
MUscle Side-Effects of Atorvastatin in Coronary Patients (MUSE) -Follow-up StudyStatin Adverse ReactionNCT04453735Vestre Viken Hospital Trust27
已完成
4 期
MUscle Side-Effects of Atorvastatin in Coronary PatientsStatin Adverse ReactionNCT03874156Vestre Viken Hospital Trust77
已完成
不适用
Atorvastatin treatment in Systemic Lupus Erythematosus patientsMusculoskeletal DiseasesSystemic lupus erythematosusISRCTN51612701Polish Ministry of Science and Higher Education (Poland)60
已完成
2 期
The effect of atorvastatin on patients with multiple sclerosisIRCT2015071323184N1Arak University of Medical Sciences60
已完成
不适用
Atorvastatin and endothelial function in systemic lupus erythematosus (SLE) patientsSystemic lupus erythematosus (SLE)Musculoskeletal DiseasesSystemic lupus erythematosusISRCTN19073445State of São Paulo Research Foundation (FAPESP) (Brazil)88